(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MkfKR4VtdCCYaXHibYxqfHliQYPzZZk> NFjmXlYzPTBxNUCwM|ExODBibl2= M{HU[lI1NzR6L{eyJIg> MYHEUXNQ M4HsRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NILTe3gzPjdyN{i4NS=>
BCPAP NH7jb2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MojhNlUxNzVyMD:xNFAxKG6P M3nMTFI1NzR6L{eyJIg> NILrc4dFVVOR Mn3ibY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MV6yOlcxPzh6MR?=
K1  MnrlR4VtdCCFeXPs[UBCe3OjeR?= NFrTdlkzPTBxNUCwM|ExODBibl2= MXm3NkBp MmTXSG1UVw>? MYfhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NEfFZnEzPjdyN{i4NS=>
BCPAP NY\PS2xUS2WubDDDfYNt\SCDc4PhfS=> NX[4U5NoOjVyL{WwNE8yODByIH7N NHT4PHc4OiCq MUXEUXNQ MUXhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? MU[yOlcxPzh6MR?=
Hep3B MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[1VolbOC1zMDFOwG0> NH23UYE2KGR? NHH2coVFVVOR MWnJR|UxRTBwMEig{txO NVX0[GRwOjZ3N{WxOlc>
HCCLM3 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki3NE0yOCEQvF2= NIPYSIM2KGR? M17IemROW09? M2WxTGlEPTB;MD6xOEDPxE1? MXSyOlU4PTF4Nx?=
HuH7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XhWlAuOTBizszN MYS1JIQ> NXTuNm9yTE2VTx?= M2\UbmlEPTB;MD6yNUDPxE1? NWe2ZoNxOjZ3N{WxOlc>
HepG2 NHjxU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMVExKM7:TR?= NWrsWVl5PSCm M{O2XmROW09? NWK3UXE5UUN3ME2wMlM1KM7:TR?= NETUcokzPjV5NUG2Oy=>
SMMC7721 M3OxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXUNE0yOCEQvF2= M3XEOFUh\A>? NWS4PXU1TE2VTx?= NIfiTYhKSzVyPUCuOFEh|ryP NIHnbnozPjV5NUG2Oy=>
BEL7402 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkOWYxNTFyIN88US=> NIjpVZk2KGR? M2i1XGROW09? NW\1SXBTUUN3ME2wMlQ4KM7:TR?= MmrFNlY2PzVzNke=
MHCC97H MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHWemJqOC1zMDFOwG0> NVnTTXRnPSCm M2TvRWROW09? MkTJTWM2OD1yLkSxJO69VQ>? NUTBVFJjOjZ3N{WxOlc>
Hep3B M3mxcGNmdGxiQ4njcIUhSXO|YYm= MVywMlEwOC53L{KuOUDPxE1? NV7kNnFlPDhiaB?= NVnyPY4xTE2VTx?= MnrScIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh M2LM[VI3PTd3MU[3
HCCLM3 MVfD[YxtKEO7Y3zlJGF{e2G7 M4q3elAvOS9yLkWvNk42KM7:TR?= MVG0PEBp M2L2Z2ROW09? MlzucIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh M4\CWVI3PTd3MU[3
Hep3B NHGxOoZCeG:ydH;zbZMhSXO|YYm= MnvwNE4yNzBwNT:yMlUh|ryP NVjVXoFHPDhiaB?= NV3kUHMxTE2VTx?= NFGyfYVi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj NU\5[49EOjZ3N{WxOlc>
HCCLM3 NXrlfHNYSXCxcITvd4l{KEG|c3H5 MnTnNE4yNzBwNT:yMlUh|ryP NWfhfW04PDhiaB?= NGHmT4ZFVVOR MULhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli MXSyOlU4PTF4Nx?=
A549 M{TLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvEeFhzOC5zLUGwJO69VQ>? MWG3NkBp NHHLdJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWrtcWlXOjZ2MUWyNlU>
H157 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnh[ow6OC5zLUGwJO69VQ>? MUm3NkBp M3\BU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXriN|RrOjZ2MUWyNlU>
H1299 M3zGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;ONE4yNTFyIN88US=> NGjXNJU4OiCq MkPKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{HtWFI3PDF3MkK1
A549 MWTGeY5kfGmxbjDBd5NigQ>? M1i1fVEwOi53L{Wg{txO MWSxNkBp M4PxZuKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? MnnmNlY1OTV{MkW=
H1299 MUXGeY5kfGmxbjDBd5NigQ>? NHLMdpUyNzJwNT:1JO69VQ>? NYjpfmFpOTJiaB?= NEDveZjDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| NXfoflJtOjZ2MUWyNlU>
H157 M4X4W2Z2dmO2aX;uJGF{e2G7 MmX2NU8zNjVxNTFOwG0> NHrHSW8yOiCq Moj6[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w MoXkNlY1OTV{MkW=
H1299 NHHQbFNHfW6ldHnvckBCe3OjeR?= Mk[1NU8zNjVxNTFOwG0> MXixNkBp Mn7k[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w MUiyOlQyPTJ{NR?=
C8161 Mnm4R4VtdCCYaXHibYxqfHliQYPzZZk> MYSwMVIh|ryP NGD3eZA1KGR? NXTrN2dLTE2VTx?= NELicnZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2PH[lI3Ozl5MkKz
Mel285 MnXzR4VtdCCYaXHibYxqfHliQYPzZZk> M1vWTlAuOiEQvF2= MmLLOEBl NFPoeJZFVVOR Mmjo[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlzhNlY{QTd{MkO=
Mel290 M2r5UWNmdGxiVnnhZoltcXS7IFHzd4F6 NYnNNHczOC1{IN88US=> Mlf5OEBl NXTCcJozTE2VTx?= NEH0fWll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF;i[4kzPjN7N{KyNy=>
92.1 Ml30R4VtdCCYaXHibYxqfHliQYPzZZk> NVvPU4M3OC1{IN88US=> M{LYS|Qh\A>? Mo\LSG1UVw>? MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3z0SFI3Ozl5MkKz
Omm1.3 MnLyR4VtdCCYaXHibYxqfHliQYPzZZk> NVniZpVZOC1{IN88US=> MV20JIQ> NIHHVFBFVVOR NEjITFFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEfWd4EzPjN7N{KyNy=>
Mel202 MmjjR4VtdCCYaXHibYxqfHliQYPzZZk> Mo\mNE0zKM7:TR?= MYm0JIQ> M3:0UWROW09? MnGw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYHteVE4OjZ|OUeyNlM>
Mel270 MnziR4VtdCCYaXHibYxqfHliQYPzZZk> MkLiNE0zKM7:TR?= MXe0JIQ> M1P3ZmROW09? MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYXyb3p3OjZ|OUeyNlM>
Omm1 NHvUPHRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{HES|AuOiEQvF2= NVThOZNbPCCm MlXXSG1UVw>? NIjsS5Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUGyOlM6PzJ{Mx?=
92.1 MWfBdI9xfG:|aYOgRZN{[Xl? Mn\KOVAxKG6P MmfXOFghcA>? NVy0R2ljTE2VTx?= M4frU4lv\HWlZYOgZZBweHSxc3nz MkjwNlY{QTd{MkO=
Omm1.3 Ml;URZBweHSxc3nzJGF{e2G7 NVz3dGs6PTByIH7N M2DwVlQ5KGh? MkDXSG1UVw>? NH3HR5VqdmS3Y3XzJIFxd3C2b4Ppdy=> M{mxfVI3Ozl5MkKz
92.1 Ml7iR4VtdCCFeXPs[UBCe3OjeR?= MmfNOVAxKG6P MVeyOE81QC95MjDo MoKzSG1UVw>? MknEbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? M4TLUFI3Ozl5MkKz
Omm1.3 NHPXS49E\WyuIFP5Z4xmKEG|c3H5 MWe1NFAhdk1? Ml3JNlQwPDhxN{KgbC=> NH3Je5hFVVOR MnTTbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? NHn2NpYzPjN7N{KyNy=>
A549 NF\aXWNHfW6ldHnvckBCe3OjeR?= NGDPO5AyODBxNECwM|ExODBibl2= NGKySWszPCCq MnPPeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NFH3R|UzPjJzMkG5PS=>
MCF-7 M3\DUmZ2dmO2aX;uJGF{e2G7 Ml\QNVAxNzRyMD:xNFAxKG6P MV:yOEBp NIfvV4R2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz MXSyOlIyOjF7OR?=
HEK293 MkDBSpVv[3Srb36gRZN{[Xl? MXOxNFAwPDByL{GwNFAhdk1? MUWyOEBp M13NepVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MUmyOlIyOjF7OR?=
858 NGfLTXNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHjObZQxNTFizszN M{nCT|Uh\A>? NYf3d|FJTE2VTx?= Mnzz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3\WS|I3OjB4M{Oz
DDR2L63V M{K3fmNmdGxiVnnhZoltcXS7IFHzd4F6 NEO1UpIxNTFizszN Mlq1OUBl MULEUXNQ NYXpdHVO\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmDJNlYzODZ|M{O=
BE(2)-C NV\xXFI{S2WubDDWbYFjcWyrdImgRZN{[Xl? NFnTXG8yKM7:TR?= NYXs[GRCOS12IHS= NETHWY1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NFW1fVIzPjB4N{S2OC=>
IMR-32 MmX4R4VtdCCYaXHibYxqfHliQYPzZZk> M3f3ZVEh|ryP M{LwSFEuPCCm NXfYeZh3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MnqyNlYxPjd2NkS=
JF NUn5fFduS2WubDDWbYFjcWyrdImgRZN{[Xl? MoXkNUDPxE1? M3HzUVEuPCCm NUfiZWRr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M2TPb|I3ODZ5NE[0
BE(2)-M17 MoLrR4VtdCCYaXHibYxqfHliQYPzZZk> Mo\rNUDPxE1? MVexMVQh\A>? NVPFUJZJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? Mn\JNlYxPjd2NkS=
SK-N-SH NIi4S3JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4rt[|Eh|ryP MkDMNU01KGR? MVnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NFLMeZczPjB4N{S2OC=>
SK-N-DZ  NXX1Z25ES2WubDDWbYFjcWyrdImgRZN{[Xl? MYOxJO69VQ>? NHvEeowyNTRiZB?= M1\6NoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NEjVU44zPjB4N{S2OC=>
HMC-1.1  M{XXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\rOY82NTVyMECgcm0> MX60PEBp M1j0N2ROW09? Mn\obY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MofoNlYxPTV|MEO=
HMC-1.2 NVLNUnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW1MVUxODBibl2= MmXaOFghcA>? MUjEUXNQ NEDxdGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnTBNlYxPTV|MEO=
ROSA KIT WT  NYHuOXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe1MVUxODBibl2= MWi0PEBp MnnhSG1UVw>? NFnQXW9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVv6dZlSOjZyNUWzNFM>
ROSA KIT D816V M3\YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[1MVUxODBibl2= NETlV3o1QCCq NUfDXmNxTE2VTx?= NFnOXodqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGKyR3UzPjB3NUOwNy=>
HMC-1.1  MYnBdI9xfG:|aYOgRZN{[Xl? NWj0TG5sOjByLUWwNFAhdk1? MUi0PEBp MmjiSG1UVw>? NYjQcFFKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHBbXFmOjZyNUWzNFM>
HMC-1.2 Mn2wRZBweHSxc3nzJGF{e2G7 NGfvW3gzODBvNUCwNEBvVQ>? M2j1dVQ5KGh? M{HQOWROW09? M3HZRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1jMc|I3ODV3M{Cz
ROSA KIT WT  M{KwOmFxd3C2b4Ppd{BCe3OjeR?= MnjDNlAxNTVyMECgcm0> M1zicVQ5KGh? MWHEUXNQ MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mlz3NlYxPTV|MEO=
ROSA KIT D816V NYmxSHJFSXCxcITvd4l{KEG|c3H5 NI\yb5kzODBvNUCwNEBvVQ>? NVP0N|VnPDhiaB?= MXXEUXNQ NVLD[ph{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX\4NJJIOjZyNUWzNFM>
494H NWDEbG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;qR|czKGh? M3X0cGROW09? M2XKd2lEPTB;MD6xNlLDuTBwMEC0JO69VQ>? NFLzUmczPTl2NEW2Oi=>
493H NWXQWpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\UWGM5PzJiaB?= MnnESG1UVw>? NVPNZpdzUUN3ME2wMlA1P8LzMD6wNFkh|ryP NWrXdIt[OjV7NES1OlY>
716H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zWNVczKGh? M3LDdmROW09? MoHhTWM2OD1yLkKxNuKyOC5yM{Sg{txO M3zEXFI2QTR2NU[2
148I M3qyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xO|IhcA>? NXu2NZVSTE2VTx?= M2LWNGlEPTB;MD6yPFTDuTBwMEO1JO69VQ>? MoOwNlU6PDR3Nk[=
98Sc NIO5ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp MoHnSG1UVw>? MmXRTWM2OD1yLkGxOeKyOC5yMESg{txO NG[0bHozPTl2NEW2Oi=>
89R MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLXV3VsPzJiaB?= MnnRSG1UVw>? NV75eIFLUUN3ME2wMlEzPsLzMD6wNFMh|ryP NFS5Zo8zPTl2NEW2Oi=>
494L M2LqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\tUlNIPzJiaB?= MmiwSG1UVw>? M3TZUmlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? NU\Uc5Q{OjV7NES1OlY>
493L MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX0eZc4OiCq MUjEUXNQ Ml3UTWM2OD1yLkC1NOKyOC5yMUGg{txO MVqyOVk1PDV4Nh?=
148L M{DRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3NkBp MnK1SG1UVw>? NILUbFVKSzVyPUCuNVQ3yrFyLkCxO{DPxE1? NXHqd|lQOjV7NES1OlY>
98L M1TQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvEdmhtPzJiaB?= M2XPcWROW09? MnK2TWM2OD1yLkOwPeKyOC5yMkmg{txO M4\jUVI2QTR2NU[2
OS17 NHXMS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PGOlczKGh? NUf3R2JnTE2VTx?= NHj5ZY1KSzVyPUCuNFc6yrFyLkCwN{DPxE1? M4n4ZVI2QTR2NU[2
OS9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fHWFczKGh? M1HhRWROW09? MnX6TWM2OD1yLkSwOuKyOC5yMkig{txO MoXKNlU6PDR3Nk[=
MG63 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NkBp NYi3dmszTE2VTx?= MlPETWM2OD1yLkGxOOKyOC5yMkWg{txO MXGyOVk1PDV4Nh?=
SAOS2 M2SxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1O|IhcA>? M1[5bmROW09? NUPqcXBNUUN3ME2wMlIyP8LzMD6wNFMh|ryP MXeyOVk1PDV4Nh?=
U2OS NXjyRlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvsO|IhcA>? M2HEZWROW09? M2XNOmlEPTB;MD6xPVjDuTBwMEC4JO69VQ>? NF;zeVkzPTl2NEW2Oi=>
SJSA-1 M1Hrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmO|IhcA>? NWO4NVVTTE2VTx?= NXfZR2RlUUN3ME2wMlExOMLzMD6wNVAh|ryP MYOyOVk1PDV4Nh?=
494H NEjMV5lCeG:ydH;zbZMhSXO|YYm= MmjlNE4zPS9yLkWvNU4xKM7:TR?= M2r1flI1KGh? MXLEUXNQ MmHxbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh NYL5UmNQOjV7NES1OlY>
148I NIrIbYNCeG:ydH;zbZMhSXO|YYm= M{\MSFAvOjVxMD61M|EvOCEQvF2= MonGNlQhcA>? NY\oVI9kTE2VTx?= NYn5VXdNcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li NHzlfVkzPTl2NEW2Oi=>
OS17 NXHEUJN2SXCxcITvd4l{KEG|c3H5 MorTNE4zPS9yLkWvNU4xKM7:TR?= NX3HOo17OjRiaB?= NHvYcXdFVVOR NGjOZ2dqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MW[yOVk1PDV4Nh?=
494H M4PFcWFxd3C2b4Ppd{BCe3OjeR?= MYSx5qCK|ryP NHjSb5I1QCCq MVnEUXNQ MmrrbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NYW0d2JiOjV7NES1OlY>
148I M1zjW2Fxd3C2b4Ppd{BCe3OjeR?= M4W3blHjiIoQvF2= NEPRcmU1QCCq MUPEUXNQ M4rPeolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> M1vU[|I2QTR2NU[2
OS17 NEj5enRCeG:ydH;zbZMhSXO|YYm= M4qxWVHjiIoQvF2= M{PQS|Q5KGh? MkPySG1UVw>? NE\YNlZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> MUOyOVk1PDV4Nh?=
MOLM13 NIrvWo9CeG:ydH;zbZMhSXO|YYm= M{[2b|I2OCCwTR?= NXvjOpFmPDhiaB?= MnvrSG1UVw>? NUGzZnN{cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni MlLJNlUxPTN6MkW=
MV4-11  M4\4UWFxd3C2b4Ppd{BCe3OjeR?= MWmyOVAhdk1? NWPBRVMxPDhiaB?= NUDMTHFwTE2VTx?= MUnpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MVqyOVA2Ozh{NR?=
MOLM13 MmLKSpVv[3Srb36gRZN{[Xl? M2P3fFI2OCCwTR?= NHP4SlIzPCCq NIDlb41FVVOR M{\BdIVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= MV:yOVA2Ozh{NR?=
MV4-11  NFmzNYZHfW6ldHnvckBCe3OjeR?= NWXUOY1bOjVyIH7N MkL0NlQhcA>? NXj1TI9qTE2VTx?= MVXlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MX:yOVA2Ozh{NR?=
MOLM13 M{C2U2Fxd3C2b4Ppd{BCe3OjeR?= MlfBNlUxKG6P MnKzOFghcA>? MlrnSG1UVw>? M1PHdYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NGfvbGkzPTB3M{iyOS=>
MV4-11  MYXBdI9xfG:|aYOgRZN{[Xl? NHvtXJkzPTBibl2= MnfIOFghcA>? NFXSd4dFVVOR NFfldIZqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk MojTNlUxPTN6MkW=
Hela NHf5R3hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NI\xNmExNTVyMDDuUS=> MlfzO|IhcA>? Mn3XSG1UVw>? Mor5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{OweFI2ODB7Mkm1
HBL-1 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnVNGlROC13MECgcm0> NEjzdVA4OiCq Ml7RSG1UVw>? Mniz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUmyOVAxQTJ7NR?=
HLY-1 NV30eVVxS2WubDDWbYFjcWyrdImgRZN{[Xl? MlPhNE02ODBibl2= NVXZSW5IPzJiaB?= NHTGSHhFVVOR NWGyToxy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFHSZXIzPTByOUK5OS=>
OCI-Ly3 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{KyWlAuPTByIH7N MVS3NkBp Ml7TSG1UVw>? NW\yN2pF\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MojzNlUxODl{OUW=
OCI-Ly10 NIPkdmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGqwNowxNTVyMDDuUS=> NXnnZnZIPzJiaB?= M2XqbWROW09? MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MonHNlUxODl{OUW=
SU-DHL-4 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1PRPFAuPTByIH7N NYP3XFlkPzJiaB?= NEO1ZVlFVVOR NFfoPIVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlvGNlUxODl{OUW=
SU-DHL-5 M3O1VGNmdGxiVnnhZoltcXS7IFHzd4F6 M4C1dVAuPTByIH7N NYfkdXBSPzJiaB?= NVfOcodOTE2VTx?= MUPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWDKclZoOjVyMEmyPVU>
SU-DHL-6 NF\kSmZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmHGNE02ODBibl2= MUS3NkBp MmT5SG1UVw>? NWTCOXJy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2fOOlI2ODB7Mkm1
SU-DHL-10 NIrsOVZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{eyfFAuPTByIH7N MVO3NkBp NYrWfFh{TE2VTx?= M3nKcoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2LOO|I2ODB7Mkm1
RC-K8 NXTTOVcxS2WubDDWbYFjcWyrdImgRZN{[Xl? NWm2[Jl{OC13MECgcm0> NVPCTWZ5PzJiaB?= NUjxZXRKTE2VTx?= M4XENYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{LK[|I2ODB7Mkm1
OCI-Ly8 NWfJemhXS2WubDDWbYFjcWyrdImgRZN{[Xl? MVuwMVUxOCCwTR?= NWPESWhUPzJiaB?= M4nNfWROW09? MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXeyOVAxQTJ7NR?=
OCL-Ly18 MmLLR4VtdCCYaXHibYxqfHliQYPzZZk> M3fHN|AuPTByIH7N MXO3NkBp M{P4OmROW09? NEnQZWtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYHncnhROjVyMEmyPVU>
OCI-Ly3 NIPTT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4Ro5JOTd{L{K1NE82ODBibl2= NWfobZNNOi95IHS= NF7IUnNFVVOR M4HSZ4lv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MYSyOVAxQTJ7NR?=
OCI-Ly8 NXfJc3NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzRfpY2OTd{L{K1NE82ODBibl2= MkDMNk84KGR? NFfiVnZFVVOR NHrQTG5qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MYKyOVAxQTJ7NR?=
SU-DHL-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6VXcyPzJxMkWwM|UxOCCwTR?= M2DT[FIwPyCm MYPEUXNQ NF7Rd|hqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg Mn\2NlUxODl{OUW=
SU-DHL-10 M3PleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xO|IwOjVyL{WwNEBvVQ>? M3HrPVIwPyCm M2DxRmROW09? MlHHbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NGjZUGczPTByOUK5OS=>
OCI-Ly3 MnPBRZBweHSxc3nzJGF{e2G7 M{\NTlE4Oi9{NUCgcm0> NUjrWlF1P2R? Ml7rSG1UVw>? NYXoXlR1cW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NVnXVnNvOjVyMEmyPVU>
OCI-Ly8 NYTtU5NoSXCxcITvd4l{KEG|c3H5 MWGxO|IwOjVyIH7N M3LVOVdl NGXMc45FVVOR MkjEbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MnXRNlUxODl{OUW=
SU-DHL-4 M4CwRWFxd3C2b4Ppd{BCe3OjeR?= MWWxO|IwOjVyIH7N MWG3[C=> NXnSfWNiTE2VTx?= NGP4TY5qdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> M120NFI2ODB7Mkm1
SU-DHL-10 MX\BdI9xfG:|aYOgRZN{[Xl? MnPhNVczNzJ3MDDuUS=> MmrvO4Q> M4H5NWROW09? NX;MZ5RjcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 MVSyOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID